JP2022515338A5 - - Google Patents

Info

Publication number
JP2022515338A5
JP2022515338A5 JP2021532368A JP2021532368A JP2022515338A5 JP 2022515338 A5 JP2022515338 A5 JP 2022515338A5 JP 2021532368 A JP2021532368 A JP 2021532368A JP 2021532368 A JP2021532368 A JP 2021532368A JP 2022515338 A5 JP2022515338 A5 JP 2022515338A5
Authority
JP
Japan
Prior art keywords
seq
promoter
nucleic acid
aav
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021532368A
Other languages
English (en)
Japanese (ja)
Other versions
JP7590968B2 (ja
JP2022515338A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/064396 external-priority patent/WO2020117898A1/en
Publication of JP2022515338A publication Critical patent/JP2022515338A/ja
Publication of JP2022515338A5 publication Critical patent/JP2022515338A5/ja
Priority to JP2024177032A priority Critical patent/JP2025011200A/ja
Application granted granted Critical
Publication of JP7590968B2 publication Critical patent/JP7590968B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021532368A 2018-12-05 2019-12-04 遺伝子送達のための組み換えアデノ随伴ウイルスベクター Active JP7590968B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024177032A JP2025011200A (ja) 2018-12-05 2024-10-09 遺伝子送達のための組み換えアデノ随伴ウイルスベクター

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862775871P 2018-12-05 2018-12-05
US62/775,871 2018-12-05
US201962801195P 2019-02-05 2019-02-05
US62/801,195 2019-02-05
US201962863126P 2019-06-18 2019-06-18
US62/863,126 2019-06-18
US201962914856P 2019-10-14 2019-10-14
US62/914,856 2019-10-14
PCT/US2019/064396 WO2020117898A1 (en) 2018-12-05 2019-12-04 Recombinant adeno-associated viral vector for gene delivery

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024177032A Division JP2025011200A (ja) 2018-12-05 2024-10-09 遺伝子送達のための組み換えアデノ随伴ウイルスベクター

Publications (3)

Publication Number Publication Date
JP2022515338A JP2022515338A (ja) 2022-02-18
JP2022515338A5 true JP2022515338A5 (https=) 2022-12-12
JP7590968B2 JP7590968B2 (ja) 2024-11-27

Family

ID=70974857

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021532368A Active JP7590968B2 (ja) 2018-12-05 2019-12-04 遺伝子送達のための組み換えアデノ随伴ウイルスベクター
JP2024177032A Pending JP2025011200A (ja) 2018-12-05 2024-10-09 遺伝子送達のための組み換えアデノ随伴ウイルスベクター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024177032A Pending JP2025011200A (ja) 2018-12-05 2024-10-09 遺伝子送達のための組み換えアデノ随伴ウイルスベクター

Country Status (11)

Country Link
US (1) US12454701B2 (https=)
EP (1) EP3890786A4 (https=)
JP (2) JP7590968B2 (https=)
KR (1) KR20220022107A (https=)
CN (1) CN113423434A (https=)
AU (1) AU2019391042A1 (https=)
BR (1) BR112021009913A2 (https=)
CA (1) CA3121177A1 (https=)
IL (1) IL283546A (https=)
MX (1) MX2021006646A (https=)
WO (1) WO2020117898A1 (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3635009T3 (da) 2017-06-07 2026-03-30 Regeneron Pharma Sammensætninger og fremgangsmåder til internalisering af enzymer
US12258597B2 (en) 2018-02-07 2025-03-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
BR112020023145A2 (pt) 2018-05-17 2021-02-02 Regeneron Pharmaceuticals, Inc. anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto
CA3114175A1 (en) 2018-10-01 2020-04-09 The Trustees Of The University Of Pennsylvania Beta-galactosidase based aav for treating gm1 gangliosidosis
KR20220022107A (ko) * 2018-12-05 2022-02-24 아베오나 테라퓨틱스 인코퍼레이티드 유전자 전달을 위한 재조합 아데노-연관 바이러스 벡터
CA3132379A1 (en) * 2019-03-22 2020-10-01 Rush University Medical Center Combination of nasal gene delivery and oral cinnamic acid, oleamide or gemfibrozil for lysosomal storage disorders
US20210082541A1 (en) * 2019-08-31 2021-03-18 Wyatt Technology Corporation Measuring attributes of a viral gene delivery vehicle sample via separation
CN113025618B (zh) * 2019-12-24 2024-02-06 朗信启昇(苏州)生物制药有限公司 一种x连锁遗传性视网膜劈裂症的基因治疗方案与应用
EP4103214B1 (en) 2020-02-13 2026-04-29 Tenaya Therapeutics, Inc. Gene therapy vectors for treating heart disease
WO2021163357A2 (en) 2020-02-13 2021-08-19 Tenaya Therapeutics, Inc. Gene therapy vectors for treating heart disease
WO2021183895A1 (en) * 2020-03-13 2021-09-16 Biomarin Pharmaceutical Inc. Treatment of fabry disease with aav gene therapy vectors
AU2021265768B2 (en) * 2020-04-27 2023-03-30 4D Molecular Therapeutics Inc. Adeno-associated variants, formulations and methods for pulmonary delivery
EP4103211A4 (en) * 2020-04-27 2023-08-23 4D Molecular Therapeutics Inc. CODON-OPTIMISED GLA GENES AND THEIR USES
GB202010981D0 (en) * 2020-07-16 2020-09-02 Ucl Business Ltd Gene therapy for neuromuscular and neuromotor disorders
KR20230117327A (ko) * 2020-09-03 2023-08-08 어빈 에스.와이. 첸 가용성 알칼리성 포스파타제 작제물 및 가용성 알칼리성 포스파타제 작제물을 인코딩하는 폴리뉴클레오티드를 포함하는 발현 벡터
CN114507692B (zh) * 2020-11-16 2024-07-12 舒泰神(北京)生物制药股份有限公司 用于治疗法布里病的腺相关病毒载体及其用途
EP4244360A4 (en) * 2020-11-16 2025-05-07 Beijing SoloBio Genetechnology Company Ltd. Recombinant adeno-associated viruses with enhanced liver tropism and uses thereof
MX2023008362A (es) * 2021-01-14 2023-10-04 Spark Therapeutics Inc Composiciones y metodos para el tratamiento de la enfermedad de fabry.
AR124981A1 (es) * 2021-02-26 2023-05-24 Takeda Pharmaceuticals Co Composición y métodos para el tratamiento de la enfermedad de fabry
JP2024519819A (ja) * 2021-05-18 2024-05-21 アビオナ・セラピュ―ティクス・インコーポレイテッド 眼疾患および障害を処置するための方法および組成物
KR20240032971A (ko) 2021-07-08 2024-03-12 테나야 테라퓨틱스, 인코포레이티드 유전자 요법을 위한 최적화된 발현 카세트
WO2023284873A1 (en) * 2021-07-15 2023-01-19 Shanghai Vitalgen Biopharma Co., Ltd. Recombinant adeno-associated viral vectors for treating bietti crystalline dystrophy
AR126877A1 (es) * 2021-08-25 2023-11-22 Canbridge Pharmaceuticals Inc PARTÍCULAS DE AAV QUE COMPRENDEN UNA PROTEÍNA DE LA CÁPSIDE HEPATOTRÓPICA Y a-GLUCOSIDASA ÁCIDA (GAA) Y SU USO PARA TRATAR LA ENFERMEDAD DE POMPE
CA3229998A1 (en) * 2021-08-25 2023-03-02 Canbridge Pharmaceuticals, Inc. Aav particles comprising a liver-tropic capsid protein and alpha-galactosidase and their use to treat fabry disease
CN114181318B (zh) * 2021-11-08 2023-08-01 四川大学 一种组织特异性表达穿透血脑屏障的idua融合蛋白的重组腺相关病毒及应用
KR20240133693A (ko) * 2021-11-12 2024-09-04 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 점액다당류증 iiia의 치료를 위한 유전자 요법
CN114381465B (zh) * 2021-12-22 2024-01-16 苏州诺洁贝生物技术有限公司 优化的cyp4v2基因及其用途
EP4511482A4 (en) * 2022-04-19 2026-03-18 Shanghai Vitalgen Biopharma Co Ltd Recombinant AAV vectors for the treatment of neurodegenerative disorders
CN115029360B (zh) * 2022-05-30 2024-08-02 上海勉亦生物科技有限公司 用于治疗粘多糖贮积症iiia型的转基因表达盒
WO2023240236A1 (en) * 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of spinal muscular atrophy related disorders
US20250369012A1 (en) * 2022-06-21 2025-12-04 Skyline Therapeutics Limited Recombinant aav for the gene therapy of sma disease
KR20240000814A (ko) * 2022-06-24 2024-01-03 연세대학교 산학협력단 망막색소상피에 특이적으로 작동하는 CRISPR/Cas 복합체를 유효성분으로 포함하는 망막질환 치료용 약학조성물
CA3262218A1 (en) 2022-07-19 2024-01-25 Rampart Bioscience, Inc. CIRCULAR NON-IMMUNOGENEOUS NON-VIRAL DNA VECTORS
WO2024054864A1 (en) 2022-09-06 2024-03-14 Tenaya Therapeutics, Inc. Cardioprotective heart disease therapies
CN118715316B (zh) * 2022-10-08 2025-09-19 凌意(杭州)生物科技有限公司 用于治疗GCase缺乏相关疾病的多核苷酸
CN115960177B (zh) * 2022-10-09 2023-07-07 广州派真生物技术有限公司 腺相关病毒突变体及其应用
KR20240086741A (ko) * 2022-11-28 2024-06-19 (주)지뉴인텍 Pde6b 유전자가 포함된 아데노연관바이러스 재조합 벡터를 유효성분으로 포함하는 유전성 망막질환 예방 또는 치료용 조성물
IT202300004443A1 (it) * 2023-03-09 2024-09-09 Int Centre For Genetic Engineering And Biotechnology Icgeb Sequenza codificante per alfa galattosidasi a umana per il trattamento della malattia di fabry
WO2024215655A1 (en) 2023-04-10 2024-10-17 Tenaya Therapeutics, Inc. Cardioprotective bag3 therapies
WO2024215653A1 (en) 2023-04-10 2024-10-17 Tenaya Therapeutics, Inc. Guide rnas, vectors, and virions for targeting mutations in the pln gene
AU2024257162A1 (en) * 2023-04-17 2025-11-06 Exegenesis Bio Singapore Pte. Ltd. Compositions and methods for gene therapies
EP4704920A1 (en) * 2023-05-04 2026-03-11 Abeona Therapeutics Inc. Recombinant adeno-associated viral vectors for multipartite gene delivery and stargardt disease treatment
WO2024233669A2 (en) * 2023-05-11 2024-11-14 Saliogen Therapeutics, Inc. Compositions and methods for treatment of cystic fibrosis
EP4711461A1 (en) * 2023-05-12 2026-03-18 Genecombio Ltd. Viral vector carrying smn gene expression cassette and use thereof
CN116622750B (zh) * 2023-06-01 2024-05-31 上海勉亦生物科技有限公司 优化的人法布里转基因表达盒及其用途
CN121548647A (zh) * 2023-06-09 2026-02-17 4D分子治疗有限公司 腺伴随病毒制剂
WO2025030426A1 (en) * 2023-08-09 2025-02-13 Chigenovo Co., Ltd. Pharmaceutical preparations for treating bietti's crystalline dystrophy
WO2025039622A1 (zh) * 2023-08-23 2025-02-27 上海金珂博生物技术有限公司 经修饰的腺相关病毒载体及其在治疗中枢神经系统疾病中的用途
WO2025090786A1 (en) * 2023-10-24 2025-05-01 Rampart Bioscience, Inc. Reduced immunogenic gene therapy protocols using circular, extended cruciform containing non-viral vectors
WO2025092951A1 (en) * 2023-11-03 2025-05-08 Shanghai Vitalgen Biopharma Co., Ltd. Recombinant adeno-associated viral vectors for treating fabry disease
WO2026072721A1 (en) * 2024-09-25 2026-04-02 Carbon Biosciences, Inc. Parvovirus compositions and methods for gene therapy

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9101433D0 (sv) 1991-05-13 1991-05-13 Marianne Hansson Recombinant dna sequence and its use
US6582692B1 (en) 1999-11-17 2003-06-24 Avigen, Inc. Recombinant adeno-associated virus virions for the treatment of lysosomal disorders
US7638120B2 (en) 2000-03-14 2009-12-29 Thomas Jefferson University High transgene expression of a pseudotyped adeno-associated virus type
US7056502B2 (en) 2000-04-28 2006-06-06 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with AAV5 capsids and AAV5 vectors pseudotyped in heterologous capsids
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
DE10120265A1 (de) 2001-04-25 2002-11-14 Deutsches Krebsforsch AAV-Helferplasmide zur Helfervirus-freien Verpackung und Pseudotypisierung von AAV-Vektoren
DK2573170T3 (en) 2001-12-17 2018-04-09 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 9, vectors containing them, and their use
EP1620133B1 (en) 2003-05-01 2015-12-09 Genzyme Corporation Gene therapy for neurometabolic disorders
US9233131B2 (en) 2003-06-30 2016-01-12 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
EP2345731B1 (en) 2003-09-30 2015-10-21 The Trustees of the University of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
US7527947B2 (en) 2004-06-14 2009-05-05 Novozymes A/S Signal peptide for producing a polypeptide
ES2525067T3 (es) 2005-04-07 2014-12-17 The Trustees Of The University Of Pennsylvania Método de incremento de la función de un vector de AAV
US7867484B2 (en) 2006-01-27 2011-01-11 University Of North Carolina At Chapel Hill Heparin and heparan sulfate binding chimeric vectors
CN103849629B (zh) 2006-06-21 2017-06-09 尤尼克尔Ip股份有限公司 具有经修饰的用于在昆虫细胞中产生aav的aav‑rep78翻译起始密码子的载体
CA2665620A1 (en) * 2006-10-12 2008-04-17 Copernicus Therapeutics Inc. Codon optimized cftr
EP2019143A1 (en) 2007-07-23 2009-01-28 Genethon CNS gene delivery using peripheral administration of AAV vectors
EP2058401A1 (en) 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
WO2009137006A2 (en) 2008-04-30 2009-11-12 The University Of North Carolina At Chapel Hill Directed evolution and in vivo panning of virus vectors
US9415121B2 (en) 2008-12-19 2016-08-16 Nationwide Children's Hospital Delivery of MECP2 polynucleotide using recombinant AAV9
EP2561073B1 (en) 2010-04-23 2016-08-24 University of Massachusetts Cns targeting aav vectors and methods of use thereof
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
WO2012057363A1 (ja) 2010-10-27 2012-05-03 学校法人自治医科大学 神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン
CN105755044A (zh) * 2011-04-22 2016-07-13 加利福尼亚大学董事会 具有变异衣壳的腺相关病毒病毒体及其使用方法
IL287381B2 (en) * 2011-11-14 2024-04-01 Astellas Inst For Regenerative Medicine Pharmaceutical preparations of human rpe cells and uses thereof
US9434928B2 (en) 2011-11-23 2016-09-06 Nationwide Children's Hospital, Inc. Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
WO2013174760A1 (en) 2012-05-25 2013-11-28 Deutsches Krebsforschungszentrum Optimized aav-vectors for high transduction rates in dendritic cells
EP2900686B1 (en) 2012-09-28 2020-06-10 The University of North Carolina At Chapel Hill Aav vectors targeted to oligodendrocytes
EP2840140B2 (en) 2012-12-12 2023-02-22 The Broad Institute, Inc. Crispr-Cas based method for mutation of prokaryotic cells
AU2014255665B2 (en) * 2013-04-18 2018-08-02 Fondazione Telethon Effective delivery of large genes by dual AAV vectors
EP3151866B1 (en) 2014-06-09 2023-03-08 Voyager Therapeutics, Inc. Chimeric capsids
EP4344741A3 (en) 2014-11-21 2024-08-28 The University of North Carolina at Chapel Hill Aav vectors targeted to the central nervous system
CA3012344A1 (en) 2016-02-12 2017-08-17 University Of Massachusetts Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
IL305149A (en) * 2016-07-26 2023-10-01 Biomarin Pharm Inc Novel adeno-associated virus capsid proteins
WO2018178067A1 (en) * 2017-03-27 2018-10-04 Vrije Universiteit Brussel Diaphragm-specific nucleic acid regulatory elements and methods and use thereof
JP7371083B2 (ja) 2018-07-20 2023-10-30 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ 遺伝子治療発現ベクターの眼内送達
KR20220022107A (ko) 2018-12-05 2022-02-24 아베오나 테라퓨틱스 인코퍼레이티드 유전자 전달을 위한 재조합 아데노-연관 바이러스 벡터
JP2024519819A (ja) 2021-05-18 2024-05-21 アビオナ・セラピュ―ティクス・インコーポレイテッド 眼疾患および障害を処置するための方法および組成物

Similar Documents

Publication Publication Date Title
JP2022515338A5 (https=)
US10369232B2 (en) Allele selective gene editing and uses thereof
JP2024095717A5 (https=)
JP2021502060A5 (https=)
JP7832262B2 (ja) 肝特異的ウイルスプロモーター及びその使用方法
JP2021529513A5 (https=)
JP2023534999A5 (https=)
CN114450031A (zh) 靶向rna的敲低和替代组合物及使用方法
IL308514B1 (en) Aav treatment of huntington's disease
JP2023535956A5 (https=)
JP2022531861A5 (https=)
US12037588B2 (en) Compositions and methods comprising engineered short nuclear RNA (snRNA)
WO2023154807A2 (en) Compositions and methods for modulating pre-mrna splicing
JP2024523707A5 (https=)
KR20210096168A (ko) 신경퇴행성 질환을 위한 유전자 요법
JP2023523622A5 (https=)
IL279091B1 (en) Compositions and methods for treating dominant retinitis pigmentosa
JP2021525531A5 (https=)
JP2022553573A5 (https=)
JP2020535804A5 (https=)
JP2024513907A5 (https=)
JP2024541319A5 (https=)
JP2025513066A5 (https=)
JP2024530023A5 (https=)
JP2024519819A5 (https=)